Current WHO-endorsed molecular diagnostics for the detection of DR-TB can be used to detect only a limited number of target gene regions and are not ideal for the detection of novel mutations located outside the targeted region or phenotypic resistance conferred by mutations across large gene regions, such as pncA for PZA, even atpE (18), Rv0678 (19), and pepQ (20) for the novel drug BDQ and ddn, fgd1, fbiA, fbiB, and fbiC (21) for the novel drug DLM, and Rv0678 (19) and Rv1979c (22) for the repurposed drug CFZ and rrl (23) and rplC (24) for the repurposed drug LZD. This evidence concerns the gene FGD1 and tuberculosis.